a 48-week phase ii open , uncontrolled study of auranofin ( af ) in patients juvenile rheumatoid arthritis ( jra ) was conducted to assess efficacy , tolerance and serum gold levels , and to consider the feasibility of further controlled studies ( phase iii ) in such patients .
C0004320
auranofin
C0018026
gold